De Caridi Giovanni, Massara Mafalda, Barilla Chiara, Benedetto Filippo
Dipartimento di Scienze Biomediche, Odontoiatriche e delle Immagini Morfologiche e Funzionali, Università di Messina, 98122 Messina, Italy.
Divisione di Chirurgia Vascolare ed Endovascolare, GOM di Reggio Calabria, 89124 Reggio Calabria, Italy.
Med Sci (Basel). 2025 Jun 1;13(2):71. doi: 10.3390/medsci13020071.
Peripheral prosthetic vascular graft infection represents a very serious complication after lower limb revascularization, with amputation and mortality rates up to 70% and 30%, respectively. This study was designed to determine the incidence of prosthetic graft infection, amputation, and mortality rate in our institution, analyzing different types of treatment. A retrospective cohort single institution review of peripheral prosthetic bypass grafts evaluated patient demographics, comorbidities, indications, location of bypass, type of prosthetic material, and case urgency and evaluated the incidence of graft infections, amputations, and mortality. Between January 2016 and December 2021, a total of 516 bypasses were recorded (318 male, 198 female, mean age 74.2): 320 bypasses in venous material and 196 prosthetic bypasses using Dacron or PTFE. Among patients with a prosthetic bypass, 16 (8.2%) presented a graft infection at a mean follow-up of 39 months. Thirteen other patients who submitted to prosthetic peripheral bypass in other centers presented to our institution with a graft infection, so a total of 29 infected grafts were treated. Infected grafts were removed in 20 patients (68.9%), while a conservative treatment was helpful in nine cases (31.1%). The germs involved were Gram-negative in 27.6% and Gram-positive in 41.4%. During follow-up, we recorded five deaths (17.2%) and six amputations (20.7%) directly after bypass excision; another two amputations (6.9%) occurred after failure of the new bypass replacing the prosthesis removed. Redo-bypass, active infection at the time of bypass, and advanced gangrene were associated with a higher risk for prosthetic graft infection and major extremity amputation. Complete graft removal and replacement by venous material or Omniflow II represents the typical treatment. However, aggressive local treatment including drainage, debridement, vacuum-assisted closure therapy application, and muscle transposition seem to be a better solution in selected patients without the need for graft removal and with rates of limb salvage superior to those obtained with excisional therapy.
外周人工血管移植感染是下肢血管重建术后一种非常严重的并发症,截肢率和死亡率分别高达70%和30%。本研究旨在确定我院人工血管移植感染、截肢和死亡率的发生率,并分析不同类型的治疗方法。对周围人工血管旁路移植进行回顾性队列单机构研究,评估患者的人口统计学特征、合并症、适应症、旁路位置、人工材料类型和病例紧急程度,并评估移植感染、截肢和死亡率的发生率。2016年1月至2021年12月期间,共记录了516例旁路手术(男性318例,女性198例,平均年龄74.2岁):320例采用静脉材料旁路手术,196例采用涤纶或聚四氟乙烯人工血管旁路手术。在接受人工血管旁路手术的患者中,16例(8.2%)在平均39个月的随访中出现移植感染。另外13例在其他中心接受人工外周旁路手术的患者因移植感染前来我院治疗,因此共治疗了29例感染移植血管。20例患者(68.9%)的感染移植血管被移除,而9例患者(31.1%)采用保守治疗有效。感染涉及的细菌中革兰氏阴性菌占27.6%,革兰氏阳性菌占41.4%。在随访期间,我们记录到5例死亡(17.2%)和6例在旁路切除术后直接截肢(20.7%);另外2例截肢(6.9%)发生在新的旁路替代移除的假体失败后。再次旁路手术、旁路手术时的活动性感染和晚期坏疽与人工血管移植感染和主要肢体截肢的较高风险相关。完全移除移植血管并采用静脉材料或Omniflow II进行替代是典型的治疗方法。然而,在部分患者中,积极的局部治疗,包括引流、清创、应用负压封闭引流疗法和肌肉移位,似乎是一种更好的解决方案,无需移除移植血管,肢体挽救率高于切除治疗。